WAY-302159

CAS No. 62802-77-1

WAY-302159( —— )

Catalog No. M29001 CAS No. 62802-77-1

WAY-302159 is a VEGFR2 inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 72 In Stock
10MG 125 In Stock
25MG 260 In Stock
50MG 410 In Stock
100MG 605 In Stock
500MG 1287 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WAY-302159
  • Note
    Research use only, not for human use.
  • Brief Description
    WAY-302159 is a VEGFR2 inhibitor.
  • Description
    WAY-302159 is a VEGFR2 inhibitor.(In Vitro):WAY-302159 Inhibited VEGF-induced proliferation in HUVEC cell.
  • In Vitro
    VEGFR-2-IN-29 (Compound 5) (72 h) inhibits HUVEC proliferation. Cell Proliferation Assay Cell Line:HUVEC Concentration:Incubation Time: 72 h Result:Showed inhibition with IC50s of 15.8 nM and 210 nM against VEGF- and bFGF-induced HUVEC proliferation.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    62802-77-1
  • Formula Weight
    293.282
  • Molecular Formula
    C16H11N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 20 mg/mL (68.19 mM)
  • SMILES
    [O-][N+](=O)c1cccc(c1)C(=O)Nc1cccc2cccnc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Fruquintinib

    A potent and highly selective small molecule inhibitor of VEGFR1/2/3 with IC50 of 33/3/5/0.5 nM, respectively.

  • Motesanib

    A potent, orally bioavailable, multikinase inhibitor inhibitor of VEGFR1/2/3, PDGFR and c-Kit with IC50 of 2-6 nM, 84 nM and 8 nM, respectively.

  • Pamufetinib mesylate

    Pamufetinib mesylate (TAS-115 mesylate) is a potent vascular endothelial growth factor receptor (VEGFR) antagonist and hepatocyte growth factor receptor (c-Met) inhibitor used in the study of cancer and respiratory diseases.